References

1. Linkens AEMJH, Milosevic V, van der Kuy PHM, et al. Medication-related hospital admissions and readmissions in older patients: an overview of literature. Int J Clin Pharm. 2020;42(5):1243–51; https://doi.org/10.1007/s11096-020-01040-1.
2. Wallerstedt SM, Hoffmann M, Lönnbro J. Methodological issues in research on drug-related admissions: A meta-epidemiological review with focus on causality assessments. Br J Clin Pharmacol. 2022 Feb 1;88(2):541–50; https://doi.org/10.1111/bcp.15012.
3. El Morabet N, Uitvlugt EB, van den Bemt BJF, et al. Prevalence and Preventability of Drug-Related Hospital Readmissions: A Systematic Review. J Am Geriatr Soc. 2018 Mar 1;66(3):602–8; https://doi.org/10.1111/jgs.15244.
4. Ayalew MB, Tegegn HG, Abdela O. Drug Related Hospital Admissions; A Systematic Review of the Recent Literatures. Bull Emerg Trauma. 2019;7(4):339–46; https://doi.org/10.29252/beat-070401.
5. PCNE. PCNE Classification for Drug-Related Problems V9.1 [Internet]. Pharmaceutical Care Network Europe Association. 2020 [cited 2022 Jan 7]. p. 10. Available from: https://www.pcne.org/working-groups/2/drug-related-problem-classification
6. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83; https://doi.org/10.1016/0021-9681(87)90171-8.
7. García-Pérez L, Linertová R, Lorenzo-Riera A, et al. Risk factors for hospital readmissions in elderly patients: a systematic review. QJM An Int J Med. 2011 Aug 1;104(8):639–51; https://doi.org/10.1093/qjmed/hcr070.
8. Lea M, Mowe M, Mathiesen L, et al. Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. PLoS One. 2019 Jul 22;14(7):e0220071; https://doi.org/10.1371/journal.pone.0220071.
9. Nymoen LD, Björk M, Flatebø TE, et al. Drug-related emergency department visits: prevalence and risk factors. Intern Emerg Med. 2022; https://doi.org/10.1007/s11739-022-02935-9.
10. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev. 2016;CD008986; https://doi.org/10.1002/14651858.CD008986.pub3.
11. Kempen TGH, Bertilsson M, Hadziosmanovic N, et al. Effects of Hospital-Based Comprehensive Medication Reviews Including Postdischarge Follow-up on Older Patients’ Use of Health Care: A Cluster Randomized Clinical Trial. JAMA Netw Open. 2021 Apr 30;4(4):e216303–e216303; https://doi.org/10.1001/jamanetworkopen.2021.6303.
12. Kempen TGH, Bertilsson M, Lindner K-J, et al. Medication Reviews Bridging Healthcare (MedBridge): Study protocol for a pragmatic cluster-randomised crossover trial. Contemp Clin Trials. 2017 Oct;61:126–32; https://doi.org/10.1016/j.cct.2017.07.019.
13. Kempen TGH, Hedström M, Olsson H, et al. Assessment tool for hospital admissions related to medications: development and validation in older patients. Int J Clin Pharm. 2019;41(1); https://doi.org/10.1007/s11096-018-0768-8.
14. Howard RL, Avery AJ, Howard PD, et al. Investigation into the reasons for preventable drug related admissions to a medical admissions unit: observational study. Qual Saf Heal Care. 2003 Aug;12(4):280–5; https://doi.org/10.1136/qhc.12.4.280.
15. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990 Mar;47(3):533–43.
16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60; https://doi.org/10.1016/j.jhep.2018.03.024.
17. Weersink RA, Burger DM, Hayward KL, et al. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations. Expert Opin Drug Metab Toxicol. 2020 Jan 2;16(1):45–57; https://doi.org/10.1080/17425255.2020.1702022.
18. Alassaad A, Melhus H, Hammarlund-Udenaes M, et al. A tool for prediction of risk of rehospitalisation and mortality in the hospitalised elderly: secondary analysis of clinical trial data. BMJ Open. 2015 Feb 1;5(2):e007259; https://doi.org/10.1136/bmjopen-2014-007259.
19. Leendertse AJ, Egberts ACG, Stoker LJ, et al. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med. 2008 Sep;168(17):1890–6; https://doi.org/10.1001/archinternmed.2008.3.
20. Wimmer BC, Dent E, Bell JS, et al. Medication Regimen Complexity and Unplanned Hospital Readmissions in Older People. Ann Pharmacother. 2014 May 27;48(9):1120–8; https://doi.org/10.1177/1060028014537469.
21. Tsuyuki RT, McKelvie RS, Arnold JMO, et al. Acute Precipitants of Congestive Heart Failure Exacerbations. Arch Intern Med. 2001 Oct 22;161(19):2337–42; https://doi.org/10.1001/archinte.161.19.2337.
22. Goyal P, Kneifati-Hayek J, Archambault A, et al. Prescribing Patterns of Heart Failure-Exacerbating Medications Following a Heart Failure Hospitalization. JACC Hear Fail. 2020;8(1):25–34; https://doi.org/10.1016/j.jchf.2019.08.007.
23. Katzenberg G, Deacon A, Aigbirior J, et al. Management of chronic obstructive pulmonary disease. Br J Hosp Med. 2021 Jul 2;82(7):1–10; https://doi.org/10.12968/hmed.2020.0561.
24. Molimard M, Raherison C, Lignot S, et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur Respir J. 2017 Feb 1;49(2):1601794; https://doi.org/10.1183/13993003.01794-2016.
25. Klatte DCF, Gasparini A, Xu H, et al. Association Between Proton Pump Inhibitor Use and Risk of Progression of Chronic Kidney Disease. Gastroenterology. 2017;153(3):702–10; https://doi.org/10.1053/j.gastro.2017.05.046.
26. Brusselaers N, Wahlin K, Engstrand L, et al. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017 Oct 1;7(10):e017739; https://doi.org/10.1136/bmjopen-2017-017739.
27. Brusselaers N, Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018;53:172–7; https://doi.org/10.1016/j.canep.2018.02.004.
28. Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev. 2021;26(6):1359–70; https://doi.org/10.1007/s10741-020-09979-z.
29. Cooke CE, Sidel M, Belletti DA, et al. Review: clinical inertia in the management of chronic obstructive pulmonary disease. COPD. 2012 Feb;9(1):73–80; https://doi.org/10.3109/15412555.2011.631957.
30. Kempen TGH, Cam H, Kälvemark A, et al. Intervention fidelity and process outcomes of medication reviews including post-discharge follow-up in older hospitalized patients: process evaluation of the MedBridge trial. J Clin Pharm Ther. 2020 Mar 14; https://doi.org/10.1111/jcpt.13128.